Neurocrine Biosciences, Inc. (NBIX) fair value analysis
Nasdaq · Updated 2026-10-19
NBIX price how computed
Forward Fair Value verdict
UndervaluedNBIX is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $135.71
- Sector
- Healthcare
- 12-month range
- $123.10–$185.50
- Market cap
- $13.8B
- From 52-week high
- -26.8%
- Shares outstanding
- 102M
- Rank in Healthcare by discount to fair value
- #5 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Neurocrine Biosciences, Inc. is a biopharmaceutical company that develops and commercializes medications for neurological, endocrine, and psychiatric disorders. The company operates primarily in the United States and markets its products globally.
NBIX currently ranks #5 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $13.8B
- P/E (trailing)
- 16x
- Revenue (TTM)
- $3.37B
- Net margin
- 20.9%
- EPS (TTM)
- $8.35
- Gross margin
- 97.6%
- Debt / equity
- 0.11
- Revenue growth (3-yr avg)
- 30.8%
- Shares outstanding
- 102M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 31 · neutral
- 50-day average
- $149.26
- 200-day average
- $147.04
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-02 (post-market)
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+25.5%)
2026-03 ▲ beat (+14.1%)
2025-12 ▼ miss (-18.3%)
2025-09 ▲ beat (+4.8%)
2025-06 ▲ beat (+10.0%)
2025-03 ▼ miss (-35.8%)
2024-12 ▼ miss (-12.4%)
2024-09 ▼ miss (-0.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 25 buy · 4 hold · 0 sell (29 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $207
- Target vs last price
- +52.5%
What our data shows for NBIX
- Our model validated 17 trailing price-to-earnings windows for NBIX, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $123.10–$185.50.
- The 14-day relative strength index sits at a neutral 31.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for NBIX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent NBIX news
TickrTrends' derived news-sentiment signal for NBIX is currently leaning positive, computed from recent coverage.
- Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Undervalued -- GF Score: 90/100 (gurufocus.com, 2026-10-20)
TickrTrends take: Neurocrine Biosciences trades with a GF Score of 90 out of 100, indicating strong fundamental quality metrics that align with TickrTrends' undervalued assessment. For investors focused on valuation in the Healthcare sector, the combination of a high quality score and undervalued status suggests the stock may offer margin of safety at current price levels. Monitoring whether NBIX maintains this valuation gap as the stock moves could help determine if the disconnect between quality and price persists or narrows. - Neurocrine Biosciences (NBIX) Launches Phase 2 Trial for Alzheimer's Drug NBI-1117567 (gurufocus.com, 2026-10-20)
TickrTrends take: Neurocrine Biosciences is advancing its pipeline with a Phase 2 trial for an Alzheimer's candidate, which represents clinical progress in a therapeutic area with significant commercial potential. Given TickrTrends' current undervalued assessment of NBIX, investors monitoring the stock's valuation should track whether clinical data from this trial could justify or alter the current valuation multiples assigned to the company. The success or setbacks of this program could become a key factor influencing whether the stock's undervalued status persists or shifts as the market reprices the company's prospects in neurology. - NBIX Reiterated by Needham -- Price Target Maintained at $204 (gurufocus.com, 2026-10-16)
TickrTrends take: Needham's maintained price target of $204 for NBIX suggests the analyst sees stable value in the company despite market movements. Against TickrTrends' current undervalued assessment for this Healthcare sector company, the reiteration indicates that analyst support remains consistent with longer-term value positioning. Investors focused on valuation metrics should monitor whether NBIX's fundamentals continue to support closure of any gap between current trading levels and the analyst's maintained target.
More NBIX news
- Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued (gurufocus.com, 2026-10-13)
- NBIX Maintained by BMO Capital -- Price Target Lowered to $150 (gurufocus.com, 2026-10-12)
- NBIX Assumed by Guggenheim -- Price Target Set at $207 (gurufocus.com, 2026-10-06)
What people are saying
Follow the NBIX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — NBIX has moved from an oversold RSI zone to a neutral zone this week, indicating a shift in its momentum indicators. The stock's current valuation verdict remains Undervalued according to TickrTrends' derived indicators.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — NBIX has moved into oversold territory this week as its Relative Strength Index shifted from the neutral zone, while its position within Healthcare sector valuation rankings improved to number 11 from number 17, indicating a widening discount relative to peers. The stock maintains an undervalued assessment according to TickrTrends' current valuation verdict.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is NBIX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), NBIX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is NBIX's TickrTrends verdict?
NBIX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does NBIX compare to other Healthcare stocks?
NBIX ranks #5 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is NBIX overbought or oversold?
NBIX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does NBIX report earnings next?
NBIX's next earnings report is scheduled for 2026-11-02 (post-market), per the published earnings calendar.
Does NBIX usually beat earnings estimates?
Over its last 8 reported quarters NBIX beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NBIX?
Of 29 analysts covering NBIX, 25 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $207 (+52.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
NBIX vs ADMA · NBIX vs ALGN · NBIX vs ANIP · NBIX vs ASTH · NBIX vs AZN